Subscribe To
PHIO / PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO News
By Zacks Investment Research
October 12, 2023
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like more_horizontal
By InvestorPlace
October 12, 2023
Why Is Phio Pharma (PHIO) Stock Down 35% Today?
Phio Pharma (NASDAQ: PHIO ) stock is pulling back on Thursday after the immuno-oncology therapeutics company's shares underwent a major rally yesterd more_horizontal
By Zacks Investment Research
May 17, 2023
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas. more_horizontal
By InvestorPlace
April 18, 2023
Why Is PHIO Stock Down 20% Today?
It's been a big day for investors in Phio Pharmaceuticals (NASDAQ: PHIO ), unfortunately on the downside. This afternoon, PHIO stock has declined ne more_horizontal
By Benzinga
April 8, 2022
Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
Phio Pharmaceuticals Corp (NASDAQ: PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-c more_horizontal